Active Biotech's 57-57 shown to inhibit development of rheumatoid arthritis

By Lisa Kerner

Charlotte, N.C., June 26 - Active Biotech AB's pre-clinical results show that 57-57 has a significant inhibitory effect on disease development in experimental models for rheumatoid arthritis. The effects were measured by decreased joint destruction and inflammation.

When combined with prednisolone, 57-57 (known generically as paquinimod) offers an additional inhibitory effect on disease development, the company said.

Active Biotech presented the data at the annual European League Against Rheumatism conference.

Based in Lund, Sweden, Active Biotech develops pharmaceuticals for the treatment of autoimmune/inflammatory diseases and cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.